MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Deferred Tax Assets / Liabilities | ₹1,515 Cr | ₹1,705 Cr | ₹8.68 Cr | ₹48 Cr | ₹16 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of MANKIND PHARMA ?
| Year | Deferred Tax Assets / Liabilities |
|---|---|
| Mar2026 | ₹1,515 Cr |
| Mar2025 | ₹1,705 Cr |
| Mar2024 | ₹8.68 Cr |
| Mar2023 | ₹48 Cr |
| Mar2022 | ₹16 Cr |
How is Deferred Tax Assets / Liabilities of MANKIND PHARMA Trending?
| Years | Deferred Tax Assets / Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,515 Cr | -11.11 | |
| Mar2025 | ₹1,705 Cr | 19,538.48 | |
| Mar2024 | ₹8.68 Cr | -81.74 | |
| Mar2023 | ₹48 Cr | 191.02 | |
| Mar2022 | ₹16 Cr | - | |
Compare Deferred Tax Assets / Liabilities of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹105,174.6 Cr | 0.6% | 7% | 4.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹468,458.0 Cr | 0.7% | 8.1% | 16% | Stock Analytics | |
| DIVIS LABORATORIES | ₹193,383.0 Cr | 7% | 10.2% | 3.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹169,829.0 Cr | 2.5% | 11.3% | 49.6% | Stock Analytics | |
| CIPLA | ₹116,164.0 Cr | -0.3% | 4.1% | -3.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,648.0 Cr | -3.2% | -3.9% | -3% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | 0.6% |
7% |
4.1% |
| SENSEX | 0.9% |
2.2% |
-7.5% |
You may also like the below Video Courses